Share on StockTwits

Durata Therapeutics (NASDAQ:DRTX) Insider John Patrick Shannon, Jr. purchased 3,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $13.72 per share, with a total value of $41,160.00. Following the transaction, the insider now directly owns 11,000 shares in the company, valued at approximately $150,920. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on DRTX shares. Analysts at Jefferies Group cut their price target on shares of Durata Therapeutics from $15.00 to $12.00 in a research note on Friday, August 8th. Separately, analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $24.00 to $28.00 in a research note on Tuesday, July 1st. Finally, analysts at Gabelli initiated coverage on shares of Durata Therapeutics in a research note on Friday, June 20th. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Durata Therapeutics has an average rating of “Buy” and an average price target of $20.00.

Shares of Durata Therapeutics (NASDAQ:DRTX) traded up 5.45% on Wednesday, hitting $14.51. The stock had a trading volume of 489,488 shares. Durata Therapeutics has a 52-week low of $7.81 and a 52-week high of $18.17. The stock’s 50-day moving average is $15.35 and its 200-day moving average is $14.42. The company’s market cap is $388.5 million.

Durata Therapeutics (NASDAQ:DRTX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.12. On average, analysts predict that Durata Therapeutics will post $-2.74 earnings per share for the current fiscal year.

Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.